Published in Br J Cancer on April 04, 2013
Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer (neo-TN) | NCT01057069
Spectrum and frequencies of BRCA1/2 mutations in Bulgarian high risk breast cancer patients. BMC Cancer (2015) 1.38
Targeted therapy for breast cancer prevention. Front Oncol (2013) 1.12
Breast Cancer Risk - From Genetics to Molecular Understanding of Pathogenesis. Geburtshilfe Frauenheilkd (2013) 1.00
Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Res (2014) 0.99
Triple-negative breast cancer: treatment challenges and solutions. Breast Cancer (Dove Med Press) (2016) 0.95
BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer. BMC Cancer (2013) 0.91
Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer. Clin Cancer Res (2016) 0.87
Biology and Management of Patients With Triple-Negative Breast Cancer. Oncologist (2016) 0.84
Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response. Breast Cancer Res (2015) 0.84
Innovations that reach the patient: early health technology assessment and improving the chances of coverage and implementation. Ecancermedicalscience (2016) 0.84
BRCA1 germline mutation and glioblastoma development: report of cases. BMC Cancer (2015) 0.82
Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Nat Med (2016) 0.82
The unpluggable in pursuit of the undruggable: tackling the dark matter of the cancer therapeutics universe. Front Oncol (2013) 0.82
Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition. Pharmgenomics Pers Med (2014) 0.81
Evaluation of BRCA1-related molecular features and microRNAs as prognostic factors for triple negative breast cancers. BMC Cancer (2015) 0.81
Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer. Breast Cancer Res (2014) 0.80
Trial watch - inhibiting PARP enzymes for anticancer therapy. Mol Cell Oncol (2015) 0.79
ERCC1 polymorphisms as prognostic markers in T4 breast cancer patients treated with platinum-based chemotherapy. J Transl Med (2014) 0.78
Triple negative breast cancer: the kiss of death. Oncotarget (2017) 0.78
Different Array CGH profiles within hereditary breast cancer tumors associated to BRCA1 expression and overall survival. BMC Cancer (2016) 0.77
DNA repair prognostic index modelling reveals an essential role for base excision repair in influencing clinical outcomes in ER negative and triple negative breast cancers. Oncotarget (2015) 0.77
Relationship of immunohistochemistry, copy number aberrations and epigenetic disorders with BRCAness pattern in hereditary and sporadic breast cancer. Fam Cancer (2016) 0.77
Targeting DNA Replication Stress for Cancer Therapy. Genes (Basel) (2016) 0.75
Constitutive expression of AhR and BRCA-1 promoter CpG hypermethylation as biomarkers of ERα-negative breast tumorigenesis. BMC Cancer (2015) 0.75
Identification of BRCA1 Deficiency Using Multi-Analyte Estimation of BRCA1 and Its Repressors in FFPE Tumor Samples from Patients with Triple Negative Breast Cancer. PLoS One (2016) 0.75
Opportunities for improving triple-negative breast cancer outcomes: results of a population-based study. Cancer Med (2017) 0.75
The fate of BRCA1-related germline mutations in triple-negative breast tumors. Am J Cancer Res (2017) 0.75
BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer. PLoS One (2016) 0.75
Genetic and epigenetic characterization of the BRCA1 gene in Brazilian women at-risk for hereditary breast cancer. Oncotarget (2016) 0.75
Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies. Drugs (2017) 0.75
Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72
Comprehensive molecular portraits of human breast tumours. Nature (2012) 47.39
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 24.75
Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer (2004) 10.31
The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol (2002) 6.16
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol (2010) 5.50
BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene (2006) 3.91
Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol (2010) 2.12
Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinoma. Cancer (2003) 1.38
Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH. Breast Cancer Res Treat (2008) 1.36
An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Ann Oncol (2010) 1.35
A DGGE system for comprehensive mutation screening of BRCA1 and BRCA2: application in a Dutch cancer clinic setting. Hum Mutat (2006) 1.34
Distinction of hereditary nonpolyposis colorectal cancer and sporadic microsatellite-unstable colorectal cancer through quantification of MLH1 methylation by real-time PCR. Clin Cancer Res (2007) 1.33
Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol (2009) 1.33
BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years. Br J Cancer (2012) 1.24
Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy. Ann Oncol (2010) 1.15
Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors. Genes Chromosomes Cancer (2011) 1.06
Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH. Breast Cancer Res Treat (2010) 1.05
Clinical correlates of 'BRCAness' in triple-negative breast cancer of patients receiving adjuvant chemotherapy. Ann Oncol (2012) 1.04
Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness. Breast Cancer Res (2011) 1.03
The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer (2011) 1.01
Automated array-CGH optimized for archival formalin-fixed, paraffin-embedded tumor material. BMC Cancer (2007) 0.94
MLH1 promoter hypermethylation in the analytical algorithm of Lynch syndrome: a cost-effectiveness study. Eur J Hum Genet (2012) 0.94
A simple system for grading the response of breast cancer to neoadjuvant chemotherapy. Ann Oncol (2009) 0.88
Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst (1998) 3.67
Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med (1987) 3.04
Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19(ARF)) and is amplified in a subset of human breast cancers. Nat Genet (2000) 2.87
Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet (2005) 2.65
[Effects and costs of adjuvant chemotherapy for operable lymph node positive breast cancer with HER2/neu overexpression]. Ned Tijdschr Geneeskd (2006) 2.65
Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol (2005) 2.39
A multiplex PCR predictor for aCGH success of FFPE samples. Br J Cancer (2006) 2.33
Clinical spectrum of ataxia-telangiectasia in adulthood. Neurology (2009) 2.05
A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. Int J Cancer (2013) 2.01
Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up. Ann Oncol (2002) 1.80
Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin. Ann Oncol (2002) 1.78
Goblet cell carcinoid of the appendix: a specific type of carcinoma. Histopathology (2007) 1.73
Genomic deletions of MSH2 and MLH1 in colorectal cancer families detected by a novel mutation detection approach. Br J Cancer (2002) 1.65
The molecular genetics of human lung cancer. Eur Respir J (1989) 1.64
Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. J Natl Cancer Inst (1991) 1.64
Bone marrow reconstitution after high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation: effect of graft size. Ann Oncol (1994) 1.56
Mineral heterogeneity affects predictions of intratrabecular stress and strain. J Biomech (2010) 1.56
[An epidemic of epileptic seizures after consumption of herbal tea]. Ned Tijdschr Geneeskd (2002) 1.53
Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer (2003) 1.50
Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver. Int J Cancer (1991) 1.47
Monostrain, multistrain and multispecies probiotics--A comparison of functionality and efficacy. Int J Food Microbiol (2004) 1.45
Validation of 70-gene prognosis signature in node-negative breast cancer. Breast Cancer Res Treat (2008) 1.45
Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. Aliment Pharmacol Ther (2006) 1.44
The anion exchanger Ae2 is required for enamel maturation in mouse teeth. Matrix Biol (2007) 1.43
At home management of aplastic phase following high-dose chemotherapy with stem-cell rescue for hematological and non-hematological malignancies. Ann Oncol (1999) 1.41
[A very serious course of psittacosis in pregnancy]. Ned Tijdschr Geneeskd (1998) 1.39
The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy. Ann Surg Oncol (2010) 1.38
[Favorable effect of hematopoietic stem cells isolated from blood on hematologic recovery following high-dosage chemotherapy]. Ned Tijdschr Geneeskd (1993) 1.38
Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Ann Oncol (2002) 1.37
[Fatal miliary tuberculosis during treatment with infliximab]. Ned Tijdschr Geneeskd (2002) 1.37
An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Ann Oncol (2010) 1.35
Malignant effusions contain lysophosphatidic acid (LPA)-like activity. Ann Oncol (1998) 1.35
Enhanced expression and activation of the alternative oxidase during infection of Arabidopsis with Pseudomonas syringae pv tomato. Plant Physiol (1999) 1.27
The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients. Eur J Cancer (2010) 1.26
Patient motivation and informed consent in a phase I study of an anticancer agent. Eur J Cancer Clin Oncol (1984) 1.23
The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma. Histopathology (2007) 1.21
Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients. Br J Cancer (2003) 1.19
High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy. Br J Cancer (2006) 1.16
Comparison of immunocytochemistry, reverse transcriptase polymerase chain reaction, and nucleic acid sequence-based amplification for the detection of circulating breast cancer cells. Breast Cancer Res Treat (1999) 1.16
Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy. Ann Oncol (2010) 1.15
Anthropophilic mosquitoes and malaria transmission at Edea, Cameroon. Trop Med Parasitol (1993) 1.13
C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J Clin Invest (1994) 1.13
Health and growth of veal calves fed milk replacers with or without probiotics. J Dairy Sci (2005) 1.13
Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics. Breast Cancer Res Treat (2011) 1.12
Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy. Br J Cancer (2006) 1.12
Occurrence of autoantibodies to human leucocyte elastase in Wegener's granulomatosis and other inflammatory disorders. Ann Rheum Dis (1993) 1.11
In situ hybridization with fluoresceinated DNA. Nucleic Acids Res (1991) 1.09
Phosphorylation of the oestrogen receptor alpha at serine 305 and prediction of tamoxifen resistance in breast cancer. J Pathol (2009) 1.09
Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: a phase II study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol (1993) 1.07
Variations in mineralization affect the stress and strain distributions in cortical and trabecular bone. J Biomech (2006) 1.06
The detection of minimal numbers of contaminating epithelial tumor cells in blood or bone marrow: use, limitations and future of RNA-based methods. Ann Oncol (1998) 1.06
Absence of oncogene amplifications and occasional activation of N-ras in lymphoblastic leukemia of childhood. Blood (1986) 1.06
Efficient ways exist to obtain the optimal sample size in clinical trials in rare diseases. J Clin Epidemiol (2008) 1.05
Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging (2012) 1.05
Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response. Breast Cancer Res Treat (2013) 1.05
Circulating concentrations of soluble granzyme A and B increase during natural and experimental Plasmodium falciparum infections. Clin Exp Immunol (2003) 1.05
Management of intermediate-prognosis germ-cell cancer: results of a phase I/II study of Taxol-BEP. Int J Cancer (1999) 1.05
Thick-section fluorescence in situ hybridization on formalin-fixed, paraffin-embedded archival tissue provides a histogenetic profile. Am J Pathol (1994) 1.05
Segregation analysis detects a major gene controlling blood infection levels in human malaria. Am J Hum Genet (1992) 1.05
Clinical correlates of 'BRCAness' in triple-negative breast cancer of patients receiving adjuvant chemotherapy. Ann Oncol (2012) 1.04
Overexpression of the p53 tumor suppressor gene product in primary lung adenocarcinomas is associated with cigarette smoking. Am J Surg Pathol (1993) 1.04
Discordance in ERα, PR and HER2 receptor status across different distant breast cancer metastases within the same patient. Ann Oncol (2013) 1.03
The role of FDG PET/CT in patients with locoregional breast cancer recurrence: a comparison to conventional imaging techniques. Eur J Surg Oncol (2009) 1.03
High-performance liquid chromatographic analysis of the new antitumour drug SK&F 104864-A (NSC 609699) in plasma. J Pharm Biomed Anal (1990) 1.03
Differential expression and distribution of epithelial adhesion molecules in non-small cell lung cancer and normal bronchus. J Clin Pathol (2006) 1.03
The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment. Ann Oncol (2009) 1.03
The impact of preoperative MRI on breast-conserving surgery of invasive cancer: a comparative cohort study. Breast Cancer Res Treat (2008) 1.02
Biomechanical effect of mineral heterogeneity in trabecular bone. J Biomech (2008) 1.02
The mucin epiglycanin on TA3/Ha carcinoma cells prevents alpha 6 beta 4-mediated adhesion to laminin and kalinin and E-cadherin-mediated cell-cell interaction. J Cell Biol (1994) 1.01
Inflammatory mediators in children with protein-energy malnutrition. Am J Clin Nutr (1997) 1.00
A family with complement factor D deficiency. J Clin Invest (2001) 1.00
Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody. Cancer Immunol Immunother (1991) 0.99
A rapid and simple procedure for the routine detection of ras point mutations in formalin-fixed, paraffin-embedded tissues. Diagn Mol Pathol (1992) 0.99
In vitro migratory capacity of CD34+ cells is related to hematopoietic recovery after autologous stem cell transplantation. Blood (2001) 0.98
Is episialin/MUC1 involved in breast cancer progression? Cancer Lett (1995) 0.98
Comparative analysis of p53 gene mutations and protein accumulation in human non-small-cell lung cancer. Int J Cancer (1995) 0.98
Genomic organization and expression of the 3' end of the canine and feline enteric coronaviruses. Virology (1992) 0.96
Resistance to cisplatin and analogues: mechanisms and potential clinical implications. Cancer Chemother Pharmacol (1988) 0.96
Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature. Br J Cancer (2010) 0.96
Expression of adhesion molecules on CD34+ cells: CD34+ L-selectin+ cells predict a rapid platelet recovery after peripheral blood stem cell transplantation. Blood (1995) 0.94